0 rating

Origins of Radioresistance and Molecular Predictors of Rectal Adenocarcinoma Response to Chemoradiotherapy

Jeffrey Meyer, MD1 and Sergio Huerta, MD, FACS2

Over the last few decades, the management of stage II and stage III rectal cancer has undergone a gradual evolution towards trimodality therapy (surgery, chemotherapy, and radiotherapy) with the goal of reducing both distant and local–regional recurrence of disease. The combination of optimal surgical technique (total mesorectal excision [TME]) with pelvic radiotherapy and chemotherapy is now a standard form of treatment for patients with rectal cancer.

Return to top
This journal is supported by an educational grant from

LATEST ARTICLES

Our most popular articles